Atara Biotherapeutics Inc. conducted its annual meeting of stockholders on June 10, 2025. The stockholders voted on several proposals. The election of directors was approved, with AnhCo Nguyen Ph.D., Matthew K. Fust, and Gregory A. Ciongoli elected. The advisory vote to approve the compensation of named executive officers was also approved. Additionally, stockholders approved the frequency of one year for future advisory votes on executive compensation. Lastly, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.